FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2083485441> ?p ?o ?g. }

• W2083485441 endingPage "1186" @default.
• W2083485441 startingPage "1177" @default.
• W2083485441 abstract "This pilot phase II, double-blind, placebo-controlled trial of 1 month duration, with a 2-3-month open-label extension, evaluated the safety, tolerability, biologic effects, and efficacy of interleukin-2 diphtheria fusion protein (DAB486IL-2) in refractory rheumatoid arthritis (RA).Forty-five RA patients were enrolled in the trial, and were randomized, after a 3-4-week disease-modifying antirheumatic drug washout, to receive a daily intravenous dose of either DAB486IL-2 or placebo (saline) for 5 days. A blinded, third-party observer evaluated arthritis activity. Clinical response was defined as > or = 25% improvement in swollen and tender joints and > or = 25% improvement in at least 2 of 6 additional parameters. The double-blind phase was 4 weeks; placebo patients could cross over to receive open-label treatment for a maximum of 3 monthly DAB486IL-2 cycles.In the double-blind phase, 4 of 22 patients (18%) in the treated group and none in the placebo group (P = 0.05) met the criteria for clinical response. During the open-label treatment phase, 11 of 36 patients (31%) and 11 of 33 patients (33%) had a clinical response after completing 2 and 3 courses of DAB486IL-2, respectively. Adverse events included transient fever/chills (45%), nausea/vomiting (50%), elevated (< or = 3 x normal) transaminases (55%), and increased joint pain (45%). Twelve patients (8 placebo, 4 DAB486IL-2) did not complete 3 treatment cycles. No apparent differences were noted in CD4+ CD25+ cells of responders versus nonresponders, or of DAB486IL-2-treated versus placebo-treated patients.Clinical responses were noted in patients treated with DAB486IL-2 (18%) compared with placebo (0%) in the double-blind phase. In the open-label phase, 33% of patients completing 3 monthly DAB486IL-2 cycles had improvement in arthritis activity. Further studies of IL-2 diphtheria fusion proteins are warranted to elucidate factors that may predict clinical response and define mechanism(s) of action." @default.
• W2083485441 created "2016-06-24" @default.
• W2083485441 creator A5003669437 @default.
• W2083485441 creator A5014192770 @default.
• W2083485441 creator A5031151247 @default.
• W2083485441 creator A5033838025 @default.
• W2083485441 creator A5056472484 @default.
• W2083485441 creator A5066780563 @default.
• W2083485441 creator A5069789612 @default.
• W2083485441 creator A5069825208 @default.
• W2083485441 creator A5071494532 @default.
• W2083485441 creator A5075337981 @default.
• W2083485441 creator A5091758335 @default.
• W2083485441 date "1995-09-01" @default.
• W2083485441 modified "2023-10-14" @default.
• W2083485441 title "Interleukin-2 diphtheria fusion protein (dab486il-2) in refractory rheumatoid arthritis a double-blind, placebo-controlled trial with open-label extension" @default.
• W2083485441 cites W1501842015 @default.
• W2083485441 cites W1511769880 @default.
• W2083485441 cites W1512843295 @default.
• W2083485441 cites W1535854559 @default.
• W2083485441 cites W1986778299 @default.
• W2083485441 cites W1993051112 @default.
• W2083485441 cites W1996664424 @default.
• W2083485441 cites W2015865604 @default.
• W2083485441 cites W2033714424 @default.
• W2083485441 cites W2045509256 @default.
• W2083485441 cites W2048462515 @default.
• W2083485441 cites W2049359604 @default.
• W2083485441 cites W2057285746 @default.
• W2083485441 cites W2066909420 @default.
• W2083485441 cites W2085611725 @default.
• W2083485441 cites W2088158803 @default.
• W2083485441 cites W2090117651 @default.
• W2083485441 cites W2091943129 @default.
• W2083485441 cites W2093599503 @default.
• W2083485441 cites W2094435329 @default.
• W2083485441 cites W2095188728 @default.
• W2083485441 cites W2115009099 @default.
• W2083485441 cites W2125530151 @default.
• W2083485441 cites W2131840622 @default.
• W2083485441 cites W2133692536 @default.
• W2083485441 cites W2135151018 @default.
• W2083485441 cites W2145498103 @default.
• W2083485441 cites W2149377741 @default.
• W2083485441 cites W2151246967 @default.
• W2083485441 cites W2152348310 @default.
• W2083485441 cites W2165079375 @default.
• W2083485441 cites W2337516302 @default.
• W2083485441 cites W4241791800 @default.
• W2083485441 cites W4301967193 @default.
• W2083485441 doi "https://doi.org/10.1002/art.1780380902" @default.
• W2083485441 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/7575710" @default.
• W2083485441 hasPublicationYear "1995" @default.
• W2083485441 type Work @default.
• W2083485441 sameAs 2083485441 @default.
• W2083485441 citedByCount "58" @default.
• W2083485441 countsByYear W20834854412012 @default.
• W2083485441 countsByYear W20834854412013 @default.
• W2083485441 countsByYear W20834854412014 @default.
• W2083485441 countsByYear W20834854412015 @default.
• W2083485441 countsByYear W20834854412017 @default.
• W2083485441 countsByYear W20834854412018 @default.
• W2083485441 countsByYear W20834854412019 @default.
• W2083485441 crossrefType "journal-article" @default.
• W2083485441 hasAuthorship W2083485441A5003669437 @default.
• W2083485441 hasAuthorship W2083485441A5014192770 @default.
• W2083485441 hasAuthorship W2083485441A5031151247 @default.
• W2083485441 hasAuthorship W2083485441A5033838025 @default.
• W2083485441 hasAuthorship W2083485441A5056472484 @default.
• W2083485441 hasAuthorship W2083485441A5066780563 @default.
• W2083485441 hasAuthorship W2083485441A5069789612 @default.
• W2083485441 hasAuthorship W2083485441A5069825208 @default.
• W2083485441 hasAuthorship W2083485441A5071494532 @default.
• W2083485441 hasAuthorship W2083485441A5075337981 @default.
• W2083485441 hasAuthorship W2083485441A5091758335 @default.
• W2083485441 hasConcept C126322002 @default.
• W2083485441 hasConcept C141071460 @default.
• W2083485441 hasConcept C142724271 @default.
• W2083485441 hasConcept C197934379 @default.
• W2083485441 hasConcept C204787440 @default.
• W2083485441 hasConcept C27081682 @default.
• W2083485441 hasConcept C2777077863 @default.
• W2083485441 hasConcept C2777575956 @default.
• W2083485441 hasConcept C2778375690 @default.
• W2083485441 hasConcept C2778594517 @default.
• W2083485441 hasConcept C2780580376 @default.
• W2083485441 hasConcept C71924100 @default.
• W2083485441 hasConcept C90924648 @default.
• W2083485441 hasConceptScore W2083485441C126322002 @default.
• W2083485441 hasConceptScore W2083485441C141071460 @default.
• W2083485441 hasConceptScore W2083485441C142724271 @default.
• W2083485441 hasConceptScore W2083485441C197934379 @default.
• W2083485441 hasConceptScore W2083485441C204787440 @default.
• W2083485441 hasConceptScore W2083485441C27081682 @default.
• W2083485441 hasConceptScore W2083485441C2777077863 @default.
• W2083485441 hasConceptScore W2083485441C2777575956 @default.
• W2083485441 hasConceptScore W2083485441C2778375690 @default.
• W2083485441 hasConceptScore W2083485441C2778594517 @default.

• next